Genmab in new cooperation agreement  

Genmab enters cooperation agreement with Paradigm Therapeutics

Jyllands-Posten reports today that biotech company Genmab and the privately owned British company Paradigm Therapeutics Ltd have formed a broad cooperation for the development of new antibody products. Under the cooperation agreement, new targets from Paradigm's research in the genetics of common diseases, used together with Genmab's human antibody technology, will create and develop new products.

Genmab, an offshoot of the US company Medarex, is currently building a DKK 125 million (€ 17 million) factory north of Copenhagen, which is planned to open by the end of 2004. Genmab has been highly successful in attracting investors and currently has capital resources of DKK 1.6 billion for research

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×